FDA approves new obesity drug

Arena Pharmaceuticals' Belviq approved for obesity in adults

SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for obesity in adults, the agency said Wednesday.

The FDA announced the approval of Arena Pharmaceuticals' Belviq (lorcaserin hydrochloride), designed for use alongside reduced-calorie diets and exercise, for chronic weight management. Eisai will distribute the drug.

"Obesity threatens the overall well-being of patients and is a major public health concern," FDA Center for Drug Evaluation and Research director Janet Woodcock said. "The approval of this drug, used responsibly in combination with a healthy diet and lifestyle, provides a treatment option for Americans who are obese or are overweight and have at least one weight-related comorbid condition."

The drug works by activating the brain's serotinin 2C receptor, which is believed to help people eat less and feel full after eating smaller amounts of food.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Login or Register to post a comment.